Exploring the Potential Causal Relationship of Galectin Levels and Gynecologic Cancers: A Two-Sample Mendelian Randomization Study
Authors:
- Hongguo DongHDHongguo Dong
- Sipei NieSNSipei Nie
- Na NiNNNa Ni
- Ling GuoLGLing Guo
- Qiaoling LiuQLQiaoling Liu
Open Access
- 1 December 2025
- journal article
- research article
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 5017-5034
Abstract
Background: Previous studies have reported the correlation between single galectin levels and gynecologic cancers. The present study used the Mendelian randomization (MR) technique to evaluate the causal relationship between galectin levels and gynecologic cancers. Methods: Data on galectin levels (3394 individuals of the Gal-3 dataset, 3301 individuals of Gal-1, Gal-2, Gal-4, Gal-7, Gal-8, Gal-9, and Gal-10 datasets) and gynecologic cancers were obtained from the IEU Open genome-wide association study (GWAS) project, Ovarian Cancer Association Consortium (OCAC) and FinnGen consortium. Two-sample MR was performed to determine the causal relationship between galectin levels and gynecologic cancers. Meanwhile, a bi-directional MR analysis was also conducted to examine the direction of the causal relations. The results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Results: Gal-3 (OR=1.001, 95% CI: 1.000– 1.001) and Gal-8 (OR=1.001, 95% CI: 1.000– 1.002) may indicate small effects on cervical cancer. Gal-1 was suggested as risk factors for ovarian cancer (OR=1.108, 95% CI: 1.033– 1.188), high grade serous ovarian cancer (OR=1.106, 95% CI: 1.019– 1.202), and invasive mucinous ovarian cancer (OR=1.279, 95% CI: 1.041– 1.573). Gal-9 showed modest effect in ovarian cancer (OR=1.070, 95% CI: 1.000– 1.144), but significantly associated with an elevated risk of mucinous ovarian cancer (OR=1.242, 95% CI: 1.015– 1.520). Gal-10 was suggested as a protective factor against ovarian cancer (OR=0.929, 95% CI: 0.867– 0.994) and clear cell ovarian cancer (OR=0.803, 95% CI: 0.653– 0.987). Gal-2 (OR=0.779, 95% CI: 0.654– 0.929) and Gal-4 (OR=0.786, 95% CI: 0.639– 0.966) were found as protective factors for malignant neoplasm of corpus uteri. Gal-2 (OR=0.921, 95% CI: 0.851– 0.997) and Gal-10 (OR=0.892, 95% CI: 0.815– 0.977) were suggested as protective factors against endometrial cancer (endometrioid histology). Similarly, higher Gal-4 was also associated with decreased risk of endometrial cancer (OR=0.902, 95% CI: 0.840– 0.969) and endometrial cancer (endometrioid histology) (OR=0.846, 95% CI: 0.778– 0.920). Conclusion: The study explored potential causal relationships between galectin levels and gynecologic cancers. While some associations were modest, the consistent directionality across sensitivity analyses and the biological plausibility of galectins in tumor immunology suggest that these proteins warrant further investigation as potential biomarkers and therapeutic targets. Future research should validate these findings in clinical cohorts and explore underlying mechanisms.Keywords
This publication has 52 references indexed in Scilit:
- Association Between Neuroinflammation and Parkinson’s Disease: A Comprehensive Mendelian Randomization StudyMolecular Neurobiology, 2024
- Galectin-10 in serum extracellular vesicles reflects asthma pathophysiologyJournal of Allergy and Clinical Immunology, 2024
- Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and PreeclampsiaJAMA Cardiology, 2024
- The universe of galectin-binding partners and their functions in health and diseaseJournal of Biological Chemistry, 2023
- Galectin-7 promotes cisplatin efficacy by facilitating apoptosis and G3BP1 degradation in cervical cancerBiochemical Pharmacology, 2023
- Galectin-8 and -9 as prognostic factors for cervical cancerArchives of Gynecology and Obstetrics, 2022
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancerNature Genetics, 2017
- A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomizationStatistics in Medicine, 2017
- The role of galectin-4 in physiology and diseasesProtein & Cell, 2016
- Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasisBritish Journal of Cancer, 2014